Core Viewpoint - The company has officially entered the clinical trial phase for its research project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules," which is classified as a Class III medical device [1] Group 1: Product Development - The product is intended for use as an auxiliary hemostatic agent in surgical procedures to control bleeding from capillaries, veins, and small arteries [1] - The completion of clinical trials will be followed by plans for registration application and commercialization [1] Group 2: Market Impact - The initiation of clinical trials will enhance the company's product line in the surgical field [1] - The specific impact on the company's future performance remains unpredictable at this stage [1]
迈普医学：可吸收再生氧化纤维素止血颗粒进入临床试验